Menezon (Travoprost)

Travoprost binds to FP receptors in the ciliary body and scleral tissue, triggering remodeling of the extracellular matrix. This remodeling enhances uveoscleral outflow of aqueous humor, thereby decreasing intra‑ocular pressure and providing therapeutic benefit in glaucoma and ocular hypertension.

The prescribed dose is determined by the treating ophthalmologist. Typically, one drop of Menezon is instilled into the affected eye(s) once daily in the evening. Patients should follow the specific instructions provided by their healthcare professional.

Safety of travoprost in pregnancy and lactation has not been established. It should be avoided unless the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To request Menezon, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Travoprost belongs to the prostaglandin analogue class, similar to latanoprost and bimatoprost. Compared with beta‑blocker drops, prostaglandin analogues generally provide greater IOP reduction with once‑daily dosing, but individual response varies, and clinicians consider efficacy, tolerance and patient factors when selecting therapy.

Menezon should be stored at room temperature, below 25 °C, in the original bottle. Keep the container tightly closed, protect it from light and moisture, and avoid freezing. Do not use the product if the solution appears discolored or contains particles.

Menezon is administered as an ophthalmic solution. The patient should wash hands, tilt the head back, pull down the lower eyelid to create a small pocket, and place one drop into the conjunctival sac. Close the eye gently for a few seconds, avoid blinking excessively, and refrain from touching the tip of the bottle to any surface.

Serious but rare adverse events include uveitis (inflammation of the uveal tract), macular edema (central retinal swelling that can impair vision), and severe allergic reactions such as marked eye swelling or systemic hypersensitivity. Patients should seek immediate medical attention if they experience pain, vision changes, or signs of inflammation.

Menezon is contraindicated in individuals with active ocular inflammation, such as uveitis or ocular infection, and in patients with known hypersensitivity to travoprost or any component of the formulation. Caution is also advised for patients with a history of severe ocular side effects or those who are pregnant or breastfeeding without clear benefit.